98%
921
2 minutes
20
Mutations in ATP1A3 lead to different phenotypes having in common acute neurological decompensation episodes triggered by a specific circumstance and followed by sequelae. Alongside Alternating Hemiplegia of Childhood (AHC), Rapid-onset Dystonia Parkinsonism (RDP) and Cerebellar ataxia, Areflexia, Pes cavus, Optic atrophy, Sensorineural hearing loss syndrome (CAPOS), a new Relapsing Encephalopathy with Cerebellar Ataxia (RECA) phenotype was published in 2015. We describe herein eight new pediatric cases. Most of them had no specific history when the first neurological decompensation episode occurred, before the age of 5 years, triggered by fever with severe paralytic hypotonia followed by ataxia with or without abnormal movements. Neurological sequelae with ataxia as the predominant symptom were present after the first episode in three cases and after at least one subsequent relapse in five cases. Five of the eight cases had a familial involvement with one of the two parents affected. The phenotype-genotype correlation is unequivocal with the causal substitution always located at position 756. The pathophysiology of the dysfunctions of the mutated ATPase pump, triggered by fever is unknown. Severe recurrent neurological decompensation episodes triggered by fever, without any metabolic cause, should lead to the sequencing of ATP1A3.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejpn.2019.02.004 | DOI Listing |
BMC Neurol
September 2025
Department of Neurology, University Hospital, RWTH Aachen University, Pauwelsstrasse 30, Aachen, North Rhine-Westphalia, Germany.
Background: Cerebellar pathologies in adults can have a wide range of hereditary, acquired and sporadic-degenerative causes. Due to the frequency in daily hospital, especially intensive care, settings, electrolyte imbalances are an important, yet rare differential diagnosis. The hypomagnesemia-induced cerebellar syndrome (HiCS) constitutes a relevant disease entity with clinical and morphological variability due to a potential progression of symptoms and a promising causal treatment.
View Article and Find Full Text PDFJCI Insight
September 2025
Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Patients with Dravet syndrome (DS) present with severe, spontaneous seizures and ataxia. While most patients with DS have variants in the sodium channel Nav1.1 α subunit gene, SCN1A, variants in the sodium channel β1 subunit gene, SCN1B, are also linked to DS.
View Article and Find Full Text PDFArq Neuropsiquiatr
September 2025
Universidade Federal do Pará, Instituto de Ciências Biológicas, Belém PR, Brazil.
Mercury intoxication poses a significant challenge and growing threat to public health, particularly in the Amazon region. Despite a known history of neurological damage, as evidenced by Japan's Minamata disease, mercury intoxication remains underdiagnosed in Brazil. This review underscores the need for increased clinical awareness among neurologists, as mercury exposure has been linked to over 250 neurological symptoms, including cognitive impairment, cerebellar ataxia, peripheral neuropathy, and psychiatric disturbances.
View Article and Find Full Text PDFCureus
August 2025
Neurological Surgery, Punjab Institute of Neurosciences, Lahore, PAK.
Parvovirus B19 (PVB19) is an infrequent, serious, yet treatable cause of infection in immunocompromised hosts. Neurological manifestations of PVB19 are encephalitis, encephalopathy, meningitis, cerebellar ataxia, transverse myelitis, stroke, and peripheral neuropathy. The objective is to identify the exact clinical and diagnostic features specific to parvovirus B19 encephalitis for the isolation and management of the pathology.
View Article and Find Full Text PDFMov Disord Clin Pract
September 2025
Department of Physical Medicine and Rehabilitation, College of Physicians and Surgeons, Columbia University Medical Center, New York, New York, USA.
Background: The Scale for the Assessment and Rating of Ataxia (SARA) is the most used outcome measure in clinical trials for cerebellar ataxias. The minimal clinically important difference (MCID), a parameter used to assess meaningful change, is not clearly defined.
Objective: To help define MCID for SARA.